PRE Stock Overview
Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Prenetics Global Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.57 |
| 52 Week High | US$15.90 |
| 52 Week Low | US$2.85 |
| Beta | -0.11 |
| 1 Month Change | 1.56% |
| 3 Month Change | -1.30% |
| 1 Year Change | -62.39% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -96.08% |
Recent News & Updates
Prenetics Global Limited's (NASDAQ:PRE) 36% Cheaper Price Remains In Tune With Revenues
Apr 08
Prenetics Global Limited (NASDAQ:PRE) Held Back By Insufficient Growth Even After Shares Climb 30%
Jan 07Shareholder Returns
| PRE | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 45.1% | 2.1% | 1.2% |
| 1Y | -62.4% | 3.6% | 24.7% |
Return vs Industry: PRE underperformed the US Healthcare industry which returned 3.6% over the past year.
Return vs Market: PRE underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| PRE volatility | |
|---|---|
| PRE Average Weekly Movement | 15.8% |
| Healthcare Industry Average Movement | 7.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PRE's share price has been volatile over the past 3 months.
Volatility Over Time: PRE's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 400 | Danny Yeung | www.prenetics.com |
Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.
Prenetics Global Limited Fundamentals Summary
| PRE fundamental statistics | |
|---|---|
| Market cap | US$54.92m |
| Earnings (TTM) | -US$54.35m |
| Revenue (TTM) | US$21.74m |
2.5x
P/S Ratio-1.0x
P/E RatioIs PRE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRE income statement (TTM) | |
|---|---|
| Revenue | US$21.74m |
| Cost of Revenue | US$12.91m |
| Gross Profit | US$8.83m |
| Other Expenses | US$63.18m |
| Earnings | -US$54.35m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.52 |
| Gross Margin | 40.61% |
| Net Profit Margin | -249.95% |
| Debt/Equity Ratio | 0% |
How did PRE perform over the long term?
See historical performance and comparison